You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NSCLC-nonsquamous

Showing 1 - 25 of 3,541
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • MK-2870
  • +2 more
  • (no location specified)
Oct 3, 2023

Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line

Completed
  • Non-squamous NSCLC
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 1, 2022

    Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

    Not yet recruiting
    • Advanced Non-squamous Non-small-cell Lung Cancer
    • +2 more
    • Beijing, Beijing, China
      Peking University First Hospital Ethics Committee
    Sep 10, 2023

    NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

    Recruiting
    • NSCLC, Stage III
    • Beijing, Beijing, China
      Beijing Tsinghua Chang Gung Hospital
    Nov 4, 2022

    NSCLC (NSCLC) Trial (Sotorasib, Pembrolizumab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • (no location specified)
    Jun 26, 2023

    Non Small Cell Lung Cancer Trial in Cleveland (Liquid biopsy)

    Recruiting
    • Non Small Cell Lung Cancer
    • Liquid biopsy
    • Cleveland, Ohio
      Cleveland Clinic, Case Comprehensive Cancer Center
    Jan 6, 2022

    Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

    Recruiting
    • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
    • Canton, Ohio
      Gabrail Cancer and Research Center
    Jul 25, 2023

    Metastatic NSCLC, Stage III NSCLC Trial (inupadenant, Placebo, Carboplatin)

    Recruiting
    • Metastatic NSCLC
    • Stage III NSCLC
    • Fayetteville, Arkansas
    • +16 more
    Jan 25, 2023

    Non Small Cell Lung Cancer Trial in Wuhan (Carrelizumab, Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC),

    Recruiting
    • Non Small Cell Lung Cancer
    • Wuhan, China
      Wuhan Union Hospital
    Aug 27, 2021

    Non-squamous Cell NSCLC Trial in Zhengzhou (Anlotinib Combined With Pemetrexed And Carboplatin)

    Unknown status
    • Non-squamous Cell Non-Small Cell Lung Cancer
    • Anlotinib Combined With Pemetrexed And Carboplatin
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Apr 13, 2020

    NSCLC (NSCLC) Trial in Worldwide (Pemigatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Los Angeles, California
    • +41 more
    Jun 27, 2022

    NSCLC Trial in Goyang-Si (CA and Nivolumab)

    Recruiting
    • Non-small Cell Lung Cancer
    • CA and Nivolumab
    • Goyang-Si, Gyeonggi-do, Korea, Republic of
      National Cancer Center
    Apr 4, 2022

    Non Small Cell Lung Cancer, Brain Metastases Trial (Cadonilimab)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Brain Metastases
    • (no location specified)
    Apr 2, 2023

    NSCLC, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Tumor of Lung Trial in United States (drug,

    Terminated
    • Non-Small Cell Lung Cancer
    • +5 more
    • Birmingham, Alabama
    • +101 more
    Mar 8, 2022

    Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)

    Recruiting
    • Advanced Non-squamous Non-Small-Cell Lung Cancer
    • Jinan, Shandong, China
      The First Affiliated Hospital of Shandong First Medical Universi
    Dec 4, 2022

    Lung Cancer Trial in Houston (AMG 510, Cisplatin, Carboplatin)

    Recruiting
    • Lung Cancer
    • AMG 510
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 10, 2022

    Advanced NSCLC, Metastatic NSCLC Trial in Worldwide (MRTX849 Monotherapy, MRTX849 in Combination with Pembrolizumab)

    Recruiting
    • Advanced Non-Small Cell Lung Cancer
    • Metastatic Non-Small Cell Lung Cancer
    • MRTX849 Monotherapy
    • +2 more
    • Prescott Valley, Arizona
    • +134 more
    Jan 25, 2023

    NSCLC Metastatic, NSCLC Stage IIIB Trial in Italy (Gemcitabine, Pemetrexed, Cisplatin)

    Active, not recruiting
    • Non-small Cell Lung Cancer Metastatic
    • Non-small Cell Lung Cancer Stage IIIB
    • Alba, Italy
    • +47 more
    Mar 3, 2021

    NSCLC Trial in Worldwide (Pembrolizumab SC, Pembrolizumab IV, Paclitaxel)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Pembrolizumab SC
    • +6 more
    • Jonesboro, Arkansas
    • +116 more
    Aug 5, 2022

    Non Small Cell Lung Cancer Trial in Worldwide (Pemetrexed, Cisplatin, Necitumumab)

    Completed
    Has Results
    • Non Small Cell Lung Cancer
    • Nyack, New York
    • +100 more
    Dec 12, 2021

    Metastatic NSCLC Trial (Pembrolizumab coformulated with hyaluronidase, Pemetrexed, Cisplatin)

    Not yet recruiting
    • Metastatic Non-small Cell Lung Cancer
    • Pembrolizumab coformulated with hyaluronidase
    • +6 more
    • (no location specified)
    Jan 27, 2023

    NSCLC Trial in Hangzhou (sintilimab, pemetrexed, Carboplatin)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • sintilimab
    • +3 more
    • Hangzhou, Zhejiang, China
      Second Affiliated Hospital, School of Medicine, Zhejiang Univers
    Jul 11, 2022

    Carcinoma, Non-squamous Non-small-cell Lung Trial in Worldwide (Pembrolizumab, Pemetrexed, Carboplatin)

    Active, not recruiting
    • Carcinoma, Non-squamous Non-small-cell Lung
    • Pembrolizumab
    • +4 more
    • Birmingham, Alabama
    • +177 more
    Aug 22, 2022

    Small Cell Lung Cancer, NSCLC, Squamous, NSCLC, Non-squamous Trial in Worldwide (ladiratuzumab vedotin)

    Recruiting
    • Small Cell Lung Cancer
    • +8 more
    • Chandler, Arizona
    • +65 more
    Dec 19, 2022

    Locally Advanced or Metastatic NSCLC Trial in China (AK104, Tislelizumab, carboplatin)

    Not yet recruiting
    • Locally Advanced or Metastatic NSCLC
    • Bengbu, Anhui, China
    • +61 more
    Aug 10, 2023